AZRX News and Press, AzurRx BioPharma Inc. From 02/16/21

DELRAY BEACH, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, to...

These Penny Stocks May Be To Active To Ignore We’re at the start of a new week, and you better believe research is already getting done on which penny stocks to buy on Tuesday. Whether you use technical analysis, search for fundamentals, or your own “secret sauce, ...

Hot Penny Stocks To Buy According To These Analysts Are you looking for penny stocks to buy right now ? You’re not alone, and, in fact, some of the hottest names in the stock market today are these cheap stocks under $5. With the Biden Administration’s stance on small-...

AzurRx BioPharma (AZRX) enters into an agreement with PPD for its planned Phase 2 clinical trial evaluating a proprietary formulation of micronized niclosamide as a treatment for COVID-19-associated gastrointestinal infections.  PPD will manage the Phase 2 clinical trial f...

KalVista Pharmaceuticals (KALV) +207% on reporting positive results for KVD900.Comstock Holding Companies (CHCI) +163%.Applied UV (AUVI) +88% after acquiring Airocide Technology Platform.Heat Biologics (HTBX) +47% on announcing positive interim survival data from ongoing HS-110...

Phase 2 Study of oral niclosamide planned for 1H 2021 DELRAY BEACH, Fla., Feb. 09, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the developme...

DELRAY BEACH, Fla., Feb. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, to...

$8 Million Offering to Fuel Acquisitions and Clinical Studies Leading Therapeutic for COVID-19 Related Gastrointestinal Infections. MS1819 a Better Mousetrap vs Porcine Competitors. Taps into $2 Billion Gastrointestinal Therapeutic Global Market. Sufficient Capitalization to l...

AzurRx BioPharma (AZRX) has completed patient enrollment in the first cohort of Phase 2b OPTION 2 extension study evaluating MS1819 for the treatment of exocrine pancreatic insufficiency ((EPI)) in patients with cystic fibrosis ((CF)). The primary efficacy endpoint of the study is the coeffic...

DELRAY BEACH, Fla., Jan. 28, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, to...